Table 3.
Frequency and isotype distribution of anti-B2GPI and aCL antibodies in SSc patients with digital loss and controls
| Digital Loss | |||
|---|---|---|---|
| Anti-B2GPI | Cases (n=75) | Controls (n=75) | P§ |
| Any Positive, % (n) | 36 (27) | 19 (14) | 0.017 |
| IgM | 27 (20) | 15 (11) | 0.08 |
| IgA | 17 (13) | 5 (4) | 0.016 |
| IgG | 1 (1) | 0 (0) | NA |
| Isotype distribution | |||
| IgM only | 17 (13) | 12 (9) | 0.356 |
| IgA only | 9 (7) | 3 (2) | 0.086 |
| IgG only | 0 | 0 | NA |
| IgM+IgA | 7 (5) | 3 (2) | 0.246 |
| IgM+IgA+IgG | 1 (1) | 0 | NA |
| Anti-cardiolipin | |||
| Any positive % (n) | 24 (18) | 13 (10) | 0.08 |
| IgM | 19 (14) | 12 (9) | 0.248 |
| IgA | 4 (3) | 0 (0) | NA |
| IgG | 9 (7) | 3 (2) | 0.097 |
| Isotype distribution | |||
| IgM only | 13 (10) | 11 (8) | 0.615 |
| IgA only | 1(1) | 0 | NA |
| IgG only | 4(3) | 1(1) | NA |
| IgM+IgA | 0 | 0 | NA |
| IgM+IgG | 3 (2) | 1 (1) | NA |
| IgM+IgA+IgG | 3 (2) | 0 | NA |
§
P-values were calculated using a conditional logistic regression model